{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-004126","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.112922+00:00","generated_at":"2026-05-26T16:30:19.288014+00:00","sec_items":["1.01","1.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Genprex signs amended exclusive license with Univ of Pittsburgh for diabetes gene therapy, forms subsidiary","bullets":["Entered amended and restated exclusive license with Univ of Pittsburgh for T1D and T2D gene therapy using Pdx1 and MafA genes.","License includes milestone payments up to approximately $4,825,000 and low single-digit royalties on sales.","Terminated prior license agreements, including the November 2022 macrophage technology license.","Formed wholly-owned subsidiary Convergen Biotech, Inc. to focus on diabetes program development.","Plans to request FDA guidance for IND-enabling diabetes studies by the second half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-004126","json":"https://secwatch.observer/filing/0001437749-25-004126.json","markdown":"https://secwatch.observer/filing/0001437749-25-004126.md","text":"https://secwatch.observer/filing/0001437749-25-004126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925004126/0001437749-25-004126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925004126/gnpx20241220c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-26T16:30:19.288014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}